An Open-Label Study to Evaluate the Long-Term Safety of Arbaclofen Extended-Release Tablets in Multiple Sclerosis Patients With Spasticity (Study OS440-3005)

Trial Profile

An Open-Label Study to Evaluate the Long-Term Safety of Arbaclofen Extended-Release Tablets in Multiple Sclerosis Patients With Spasticity (Study OS440-3005)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2018

At a glance

  • Drugs Arbaclofen (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Osmotica Pharmaceutical
  • Most Recent Events

    • 31 May 2018 Status changed from not yet recruiting to recruiting.
    • 05 Mar 2018 Planned End Date changed from 1 Aug 2019 to 1 Feb 2020.
    • 05 Mar 2018 Planned primary completion date changed from 1 Jun 2019 to 1 Feb 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top